FDA Accepts Supplement for POKONZA by Genus Lifesciences
The FDA has accepted a supplemental application for POKONZA, an electrolyte replacement therapy containing potassium chloride.
Asset / Drug
Drug and asset intelligence for POKONZA with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.